Loxo Oncology
在场
是其中之一......
- Forbes Global 2000 (#174);
- Fortune 500 (#127);
- Global Fortune 500 (#455);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Eli Lilly 是一家在股票代码 LLY (US) 下上市的公司。
Eli Lilly 在 18 个国家有直接业务。Eli Lilly 拥有 25家子公司，其中包括 Dice Therapeutics、Eli Lilly APAC 和 Eli Lilly Argentina。
他们在：
涉及Eli Lilly的并购和融资。
- Eli Lilly 已收购 Morphic Therapeutic (公布2024八月20号).
- Eli Lilly has announced the acquisition of Point Biopharma (公布2023十二月5号).
- Eli Lilly has announced the acquisition of Point Biopharma (公布2023十月6号).
- Eli Lilly 已收购 Versanis Bio (公布2023八月15号).
- Eli Lilly has announced the acquisition of Versanis Bio (公布2023七月18号).
- Eli Lilly has announced the acquisition of Sigilon Therapeutics (公布2023六月30号).
- Eli Lilly has announced the acquisition of Dice Therapeutics (公布2023六月22号).
- Eli Lilly 已收购 Akouos (公布2022十二月2号).
- 查看更多"Eli Lilly"相关新闻 Hide news involving Eli Lilly
高管
查看带有其 15 名主要高管的组织结构图
Loxo Oncology 搜索最多的简介
- Jacob Van Naarden, Chief Executive Officer
- Philip Johnson, Senior Vice President, Development
- David Hyman, Chief Medical Officer
高管在Eli Lilly变化
- Jon MoellerJon Moeller 将于202412月31作为 Director 加入公司 (新闻发布的2024十一月20号).
- Thomas FuchsThomas Fuchs 将于202410月21作为 Chief Artificial Intelligence Officer 加入公司 (新闻发布的2024十月9号).
- Marschall Runge, Director, 将于 20248月31 退休 (新闻发布的2024八月20号).
创建提醒
跟踪 Loxo Oncology 的高管变动
健康
Eli Lilly 拥有 1,966 家竞争者，其中包括 Siemens Healthineers (德国)、IQVIA (美国(美洲)) 和 Nestlé Health Science (瑞士)。
Popular M&A news in 健康
- Radon Medical Imaging 已收购 Alpha Imaging (公布2024十一月20号).
- TowerBrook Capital Partners 已收购 R1 RCM (公布2024十一月19号).
- Kewaunee Scientific 已收购 Nu Aire (公布2024十一月6号).
健康 行业的其他推荐联系人
消息
Loxo Oncology 的最新新闻稿
- Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction | Investor Relations
- Lilly Announces Agreement To Acquire Loxo Oncology | Investor Relations
- Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305 | Investor Relations
- FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2) | Investor Relations
- Loxo Oncology Reports Third Quarter 2018 Financial Results | Investor Relations
- https://ir.loxooncology.com/docs/press-releases/2376151-Loxo-oncology-reports-third-quarter-2018-financial-results-.pdf
- Loxo Oncology to Participate in Upcoming Investor Conferences | Investor Relations
- Loxo Oncology to Announce Third Quarter 2018 Financial Results | Investor Relations
- Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress | Investor Relations
- Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer | Investor Relations
- View more press releases Close
关于 Loxo Oncology 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 David Hyman 
